Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Rebate Rule: US Pricing Proposal Becomes Congressional Piggy Bank

Executive Summary

A policy eliminating rebates in the Medicare Part D program will be delayed until Jan. 1, 2026 – and is very likely to be repealed altogether. If that staves off more draconian reforms, the biopharma industry will celebrate.

You may also be interested in...

US Employers Say Government Drug Pricing Reforms Needed To Supplement Market-Based Efforts

Annual Business Group on Health survey on employer-sponsored insurance covers pricing reform, rebate model alternatives, paying for high-cost drugs and copay coupons.

Initial US Health Plan Disclosures On Drug Rebates And Patient Cost Sharing Postponed

Postponement of the transparency requirement established via late 2020 legislation may mean data from health plans may not be publicly available until 2024.

Medicare Part D Spending Projections Revised Downward Because Of Rebates – Trustees Report

Underscoring the importance of rebates to program financials, the trustees project a steep increase in Part D reinsurance payments over next decade.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts